A real-world study to determine serious infections and cardiovascular complications in indolent non-Hodgkin lymphoma patients treated with first-line ibrutinib monotherapy or bendamustine/rituximab therapy
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 30 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology